Lv1
8 积分 2024-06-13 加入
Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC
6个月前
已完结
Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies
8个月前
已完结
Response Rate to Chemotherapy After Immune Checkpoint Inhibition in Metastatic Urothelial Cancer
8个月前
已完结
Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non–Small Cell Lung Cancer
8个月前
已完结
Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer
8个月前
已完结
Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: A national data base analysis
8个月前
已完结
SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
8个月前
已完结
Nivolumab and ipilimumab in advanced non small cell lung cancer previously treated with PD1 axis inhibition
8个月前
已完结
Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1–Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial
9个月前
已完结
The efficacy and safety of cadonilimab after first anti-PD-1 failure in the treatment of recurrent endometrial and cervical carcinoma: A retrospective, real-world study
9个月前
已完结
皖公网安备34019202002308
